Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Rheumatoid arthritis (RA), a systemic disease, is characterized by a chronic inflammatory reaction in the synovium of joints and is associated with degeneration of cartilage and erosion of juxta-articular bone. Many pro-inflammatory cytokines including TNF alpha, chemokines, and growth factors are e...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Feldmann, M, Maini, R
Format:	Journal article
Język:	English
Wydane:	2001

Podobne zapisy

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
od: Maini, R, i wsp.
Wydane: (1993)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
od: Maini, R, i wsp.
Wydane: (1994)

ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS
od: Feldmann, M, i wsp.
Wydane: (2011)

TNF alpha--a pivotal role in rheumatoid arthritis?
od: Brennan, F, i wsp.
Wydane: (1992)

Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions.
od: Taylor, P, i wsp.
Wydane: (2000)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (2001)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1995)

TNF alpha as a therapeutic target in rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1994)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
od: Feldmann, M, i wsp.
Wydane: (1995)

Development of anti-TNF therapy for rheumatoid arthritis.
od: Feldmann, M
Wydane: (2002)

What have we learnt from targeted anti-TNF therapy?
od: Feldmann, M, i wsp.
Wydane: (2010)

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.
od: Feldmann, M, i wsp.
Wydane: (2002)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1997)

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.
od: Elliott, M, i wsp.
Wydane: (1995)

Anti-TNF therapy: where have we got to in 2005?
od: Feldmann, M, i wsp.
Wydane: (2005)

Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha/anti-CD4 therapy.
od: Williams, R, i wsp.
Wydane: (2000)

Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
od: Feldmann, M, i wsp.
Wydane: (2004)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
od: Maini, R, i wsp.
Wydane: (1995)

Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy.
od: Maini, R, i wsp.
Wydane: (2000)

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
od: Maini, R, i wsp.
Wydane: (1997)

Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
od: Charles, P, i wsp.
Wydane: (1999)

Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.
od: Feldmann, M, i wsp.
Wydane: (1997)

Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (1992)

Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor alpha therapy in rheumatoid arthritis - Reply
od: Maini, R, i wsp.
Wydane: (1998)

From the laboratory to the clinic: Evaluation of cytokines in rheumatoid arthritis highlights TNF-alpha as a new therapeutic target
od: Feldmann, M, i wsp.
Wydane: (1994)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
od: Maini, R, i wsp.
Wydane: (1995)

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
od: Taylor, P, i wsp.
Wydane: (2009)

TNFα - A pivotal role in rheumatoid arthritis?
od: Brennan, F, i wsp.
Wydane: (1992)

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.
od: Brennan, F, i wsp.
Wydane: (1989)

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis.
od: Feldmann, M, i wsp.
Wydane: (2004)

The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target.
od: Feldmann, M
Wydane: (1996)

TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
od: Feldmann, M, i wsp.
Wydane: (2003)

What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
od: Feldmann, M
Wydane: (1996)

Cytokine therapy in rheumatoid arthritis.
od: Maini, R, i wsp.
Wydane: (1996)

Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
od: Feldman, M, i wsp.
Wydane: (1998)

Gene expression profiling of treatment response to anti-TNF-alpha therapy in rheumatoid arthritis
od: Meisel, C, i wsp.
Wydane: (2004)

Does bursitis of the forefoot improve in patients with rheumatoid arthritis on anti-TNF-alpha therapy?
od: Bowen, C, i wsp.
Wydane: (2007)

Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: Preclinical and clinical studies
od: Feldmann, M, i wsp.
Wydane: (2002)

TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action
od: Elliott, M, i wsp.
Wydane: (1995)

Nailfold Videocapillaroscopy in Patients with Rheumatoid Arthritis and Psoriatic Arthropathy on ANTI-TNF-ALPHA Therapy
od: Daniela Anghel, i wsp.
Wydane: (2023-06-01)